8-K: Modular Medical Announces $12.5 Million Private Placement to Fuel Growth

Modular Medical secures $12.5 million through private placements to advance its MODD1 product and FDA submission for a tubeless version.

Summary

• Modular Medical, Inc. has entered into Securities Purchase Agreements with investors for a private placement of 6,247,656 units at $1.92 per unit.
• Each unit consists of two shares of common stock and one warrant to purchase one share of common stock.
• Certain affiliates, officers, and directors of the company purchased a total of 374,478 units in the private placement.
• The private placement closed on March 26, 2025, with gross proceeds totaling approximately $12 million before deducting fees and expenses.
• Concurrently, the company entered into a subscription agreement with a foreign investor for a direct private placement of 260,417 units, generating approximately $0.5 million.
• The warrants have an exercise price of $1.12 per share and are exercisable immediately, expiring four years from the issuance date.
• The company intends to use the proceeds for general corporate purposes, working capital, supply-chain optimization, margin improvement on its MODD1 product, and preparing the submission to the FDA of a tubeless version of the MODD1 product in the third quarter of 2025.
• Newbridge Securities Corporation acted as the placement agent, receiving a cash fee of 7.25% of the gross proceeds and reimbursement for certain expenses.
• The company also issued placement agent warrants to purchase up to 874,672 shares of common stock with an exercise price of $1.40 per share.
• Titan Partners Group acted as financial advisor to the Company and was paid a fee of $100,000.

Sentiment

Score: 7

Explanation: The document is generally positive as it announces a successful capital raise. However, the high cost of placement agent fees and potential dilution temper the overall sentiment.

Positives

• The company successfully raised $12.5 million to fund its operations and product development.
• The funds will support the commercialization of the MODD1 product and the development of a tubeless version.
• The warrants have an exercise price above the par value of the common stock.
• The company is working towards obtaining the CE mark required for overseas markets.

Negatives

• The company incurred significant placement agent fees, reducing the net proceeds from the private placement.
• The issuance of warrants could dilute existing shareholders' equity.
• The company is not listing the warrants on any securities exchange or nationally recognized trading system.

Risks

• The company's plans are subject to FDA approval, which is not guaranteed.
• The company faces competition in the medical device market.
• The company's success depends on the successful commercialization of its MODD1 product.
• The company agreed not to effect or agree to effect any Variable Rate Transaction until one year after the date of closing of the Private Placement.

Future Outlook

The company intends to use the proceeds from the Private Placement for general corporate and working capital purposes and supply-chain optimization and margin improvement on its MODD1 product in preparation for broad commercial availability and preparing the submission to the FDA of a tubeless version of the MODD1 product, which the Company currently believes it will submit to the FDA in the third quarter of 2025, along with ongoing work to obtain the CE mark required for overseas markets.

Industry Context

The medical device industry is highly competitive and regulated. Companies must navigate complex regulatory pathways to bring new products to market. Funding is often required to support research and development, clinical trials, and commercialization efforts.

Comparison to Industry Standards

• Comparable companies in the medical device space, such as Insulet Corporation (PODD) and Dexcom (DXCM), also rely on capital raises to fund their growth initiatives.
• Private placements are a common method for smaller companies to raise capital without the need for a full public offering.
• The terms of the warrants, such as the exercise price and expiration date, are generally consistent with industry standards for similar financings.

Related Party Transactions

• Certain affiliates, officers and directors of the Company purchased a total of 374,478 Units in the Private Placement.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the company's increased financial stability and growth prospects.
• Customers may benefit from the improved MODD1 product and the development of a tubeless version.
• Suppliers may benefit from the company's increased production and demand for components.

Next Steps

• The company will use the proceeds to advance its MODD1 product and prepare for FDA submission.
• The company will file a registration statement covering the resale of the shares of common stock and shares of common stock underlying the warrants issued in the private placement and the concurrent direct private placement within 30 days of the Closing Date.
• The company will work towards obtaining the CE mark required for overseas markets.

Key Dates

Keywords

private placement, warrants, common stock, MODD1, FDA, Modular Medical, capital raise, securities, exercise price, offering